Witkiewicz et al. used TNBC cells treated with CDK4/6 inhibitors and an FDA-approved drug library (1,280 compounds) to identify CHK and PLK1 inhibitors specifically antagonized by functional RB, while Gong et al. applied a limited set of drugs (36 cell-cycle inhibitors) to show that inhibition of Aurora A kinase is synthetic lethal with RB1 mutation in a panel of diverse cancer cell lines (Witkiewicz et al., 2018; Gong et al., 2019). Here, RB1 is linked to cancer.